HOPA 2020: A Reported 7.0% of Patients Who Experience an Immune-Related Adverse Event With Checkpoint Inhibition Need to Be Hospitalized
This rate is consistent with clinical trial data.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.